Trials / Unknown
UnknownNCT00423644
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darinaparson | 420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2007-01-18
- Last updated
- 2013-11-14
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00423644. Inclusion in this directory is not an endorsement.